The latest preclinical data on pancreatic ductal adenocarcinoma indicate that the combination of anti-TNFR2 and CD40 agonists demonstrates superior efficacy compared to monotherapy by eliminating activated Treg cells and alleviating CD8 depletion (53). This evidence concerns the gene TNFRSF1B and pancreatic ductal adenocarcinoma.